In This Article:
-
Total Revenue: $18.5 million, a 4% increase over the third quarter of 2023.
-
NeuroStar System Revenue: $4.1 million with 49 systems shipped.
-
US Treatment Session Revenue: $13.3 million, a 2% increase year-over-year.
-
Gross Margin: 75.6%, up 980 basis points from the prior year.
-
Operating Expenses: $21.7 million, a 5% increase compared to the third quarter of 2023.
-
Net Loss: $13.3 million or $0.44 per share, compared to a net loss of $9.4 million or $0.33 per share in the prior year quarter.
-
Cash and Cash Equivalents: $20.9 million as of September 30, 2024.
-
Fourth Quarter Revenue Guidance: Expected to be $19 million to $20 million.
-
Full Year Revenue Guidance: Expected to be in the range of $71 million to $72 million.
-
Full Year Operating Expenses Guidance: Expected to be in the range of $81 million to $82 million, excluding $2 million of pre-close transaction expenses.
Release Date: November 12, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Neuronetics Inc (NASDAQ:STIM) reported a 4% increase in total revenue for the third quarter of 2024, reaching $18.5 million.
-
The company successfully shipped 49 NeuroStar systems during the quarter, contributing to a system revenue of $4.1 million.
-
Gross margin improved significantly to 75.6%, up from 65.8% in the prior year quarter, driven by a favorable product mix and absence of previous manufacturing costs.
-
The Greenbrook acquisition is expected to close in the fourth quarter, with anticipated synergies increasing from $15 million to $20 million.
-
Neuronetics Inc (NASDAQ:STIM) is implementing a buy-and-bill model for SPRAVATO, which is expected to enhance reimbursement and create an additional revenue stream.
Negative Points
-
Net loss for the third quarter was $13.3 million, an increase from the $9.4 million loss in the prior year quarter.
-
Operating expenses rose by 5% to $21.7 million, primarily due to transaction expenses incurred before the Greenbrook acquisition closing.
-
Revenue per active site decreased slightly to approximately $11,400 from $11,900 in the prior year quarter.
-
The company reduced its full-year revenue guidance, citing changes in customer purchasing patterns and reimbursement issues.
-
Neuronetics Inc (NASDAQ:STIM) is focusing more on profitability, which may come at the expense of losing some top-line revenue.
Q & A Highlights
Q: Can you explain the guidance reduction for full year 2024 and how it affects expectations for 2025? A: Stephen Furlong, CFO, explained that the Q4 guidance is based on current trends, noting a change in purchasing patterns due to reimbursement and cash flow issues experienced by customers in Q1. Although there has been some recovery, it wouldn't be responsible to forecast a full recovery in Q4. The focus is on profitability, which may impact revenue in Q4.